BRAF and melanoma: Another therapy recently approved by the FDA is the combination of atezolizumab with BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib, resulted in safe tolerability and prolonged progression-free cell survival in melanoma patients [6].